These include the gonadotropin-releasing hormone receptor antagonist Degarelix for advanced prostate cancer and the SMO receptor inhibitors Sonidegib and Vemurafenib for basal cell carcinoma [28]. This evidence concerns the gene GNRHR and basal cell carcinoma.